Purpose: To determine if IgM therapy promotes islet allo- and xenograft survival.

Methods: a) 200ug IgM was injected into new onset diabetic NOD mice (n=14) and blood glucose monitored. b) 2000 human islet equivalents (IEQs) were transplanted under the kidney capsule of diabetic BL/6s with and without IgM therapy (IgM (M) n=5; saline (S) n=6). c) 1000 IEQs were transplanted in NOD/scids (M n=4; S n=4). d) 400 Balb/C islets were transplanted under the kidney capsule (M n=6; S n=6); and 350 islets in the portal vein of diabetic BL/6 mice (M n=6; S n=3). e) 5 weeks-old BL/6 and NODs, BL/6- and NOD-VH125 mice and humanized BLT mice received IgM or Saline (5X) following which spleen and bone-marrow cells were analyzed by Flow cytometry.

Results: a) IgM reversed hyperglycemia in 70% of diabetic mice. b) With 2000 IEQS, 5/5 mice in the IgM group returned to normoglycemia, while controls became diabetic in 11±5.5 days (p<0.001). c) Transplantation with 1000 IEQs resulted in restoration of normoglycemia with or without IgM therapy. Removal of islet graft-containing kidney at >60days post-transplant reinstated T1D. d) Following allotransplantation, IgM restored normoglycemia permanently in 6/6 mice. Graft removal at 100 days posttransplant resulted in T1D. Hyperglycemia in controls returned in 10.8±4.7 days. Following intraportal transplantation, all IgM-treated mice were cured. Controls turned diabetic in 6.3±2.5 days. e) IgM mitigated autoimmunity in NODs by reducing % age of marginal zone B cells that perpetuate autoimmunity (p<0.05); by increasing transitional B cell proportions (p<0.01) indicating normalization of B cell homeostatic defects; and inhibiting plasma insulin autoantibody levels (p<0.0001). In NODVH125 mice, IgM eliminated insulin binding B cell population (p<0.0001) and in humanized BLT mice, hIgM therapy expanded the Helios+Foxp3+Treg population.

Conclusion: IgM therapy reversed T1D and promoted permanent islet graft survival indicating its clinical relevance for T1D.


M. Ma: None. K.L. Brayman: None. P. Chhabra: None.


American Diabetes Association (1-17-IBS-244 to K.L.B.); University of Virginia

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.